| Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED) (NCT00237484) | Merck Sharp & Dohme LLC | 2005-07-18 |
| A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679) (NCT00687440) | Merck Sharp & Dohme LLC | 2005-07-15 |
| Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045) (NCT00758069) | Merck Sharp & Dohme LLC | 2005-07-03 |
| A Study to Test the Tolerability of an Investigational Electroporation Device in Healthy Adults (V930-001) (NCT00721461) | Merck Sharp & Dohme LLC | 2005-07-01 |
| A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002) (NCT02012166) | Merck Sharp & Dohme LLC | 2005-07-01 |
| Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252) (NCT00723892) | Merck Sharp & Dohme LLC | 2005-07-01 |
| A Study of MK0364 in Obese Patients (0364-014) (NCT00131391) | Merck Sharp & Dohme LLC | 2005-07-01 |
| A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044) (NCT00127192) | Merck Sharp & Dohme LLC | 2005-07-01 |
| The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833) (NCT00441584) | Merck Sharp & Dohme LLC | 2005-07-01 |
| To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED) (NCT00482196) | Merck Sharp & Dohme LLC | 2005-07-01 |
| A Study to Test a Measure of Symptoms of Older Men With Low Testosterone On and Off Testosterone Replacement Treatment (P05815) (NCT00254553) | Merck Sharp & Dohme LLC | 2005-07-01 |
| A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015) (NCT00231777) | Merck Sharp & Dohme LLC | 2005-07-01 |
| To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052) (NCT00398099) | Merck Sharp & Dohme LLC | 2005-07-01 |
| Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) (NCT00128102) | Merck Sharp & Dohme LLC | 2005-06-30 |
| Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100) (NCT00686829) | Merck Sharp & Dohme LLC | 2005-06-30 |
| A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004) (NCT00112437) | Merck Sharp & Dohme LLC | 2005-06-24 |
| Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056) (NCT00496327) | Merck Sharp & Dohme LLC | 2005-06-22 |
| A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029) (NCT00127127) | Merck Sharp & Dohme LLC | 2005-06-10 |
| A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030) (NCT00127140) | Merck Sharp & Dohme LLC | 2005-06-01 |
| A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054) (NCT00489099) | Merck Sharp & Dohme LLC | 2005-06-01 |
| Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED) (NCT00787371) | Merck Sharp & Dohme LLC | 2005-06-01 |
| An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032) (NCT00111891) | Merck Sharp & Dohme LLC | 2005-06-01 |
| A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED) (NCT00379964) | Merck Sharp & Dohme LLC | 2005-06-01 |
| MK0457 in Patients With Leukemia (0457-003) (NCT00111683) | Merck Sharp & Dohme LLC | 2005-06-01 |
| A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048) (NCT00379951) | Merck Sharp & Dohme LLC | 2005-06-01 |
| Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED) (NCT00482599) | Merck Sharp & Dohme LLC | 2005-06-01 |
| A Placebo-Controlled, Double-Blinded, Randomized Trial of Remicade in Korean Patients With Rheumatoid Arthritis Despite Methotrexate (Study P04280)(COMPLETED) (NCT00202852) | Merck Sharp & Dohme LLC | 2005-06-01 |
| Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961) (NCT00421148) | Merck Sharp & Dohme LLC | 2005-05-30 |
| A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED) (NCT00104364) | Merck Sharp & Dohme LLC | 2005-05-01 |
| Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413) (NCT00704964) | Merck Sharp & Dohme LLC | 2005-05-01 |
| Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352) (NCT00202865) | Merck Sharp & Dohme LLC | 2005-05-01 |
| An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013) (NCT00097929) | Merck Sharp & Dohme LLC | 2005-05-01 |
| Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) (NCT00109538) | Merck Sharp & Dohme LLC | 2005-05-01 |
| Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED) (NCT00112372) | Merck Sharp & Dohme LLC | 2005-05-01 |
| Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017) (NCT00110188) | Merck Sharp & Dohme LLC | 2005-05-01 |
| A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002) (NCT02532868) | Merck Sharp & Dohme LLC | 2005-05-01 |
| Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505) (NCT00724295) | Merck Sharp & Dohme LLC | 2005-04-01 |
| A Double-masked, Randomized, Placebo-controlled,Pilot Study of Diquafosol Tetrasodium in Subjects Following Photorefractive Keratectomy (PRK) (NCT01381731) | Merck Sharp & Dohme LLC | 2005-04-01 |
| MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED) (NCT00533312) | Merck Sharp & Dohme LLC | 2005-04-01 |
| Impact of Infliximab in Fistulizing Crohn's Disease on Health Care Resources (Study P04204)(TERMINATED) (NCT00705471) | Merck Sharp & Dohme LLC | 2005-04-01 |
| Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED) (NCT00850616) | Merck Sharp & Dohme LLC | 2005-04-01 |
| Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED) (NCT00108017) | Merck Sharp & Dohme LLC | 2005-04-01 |
| A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014) (NCT00106145) | Merck Sharp & Dohme LLC | 2005-04-01 |
| MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036) (NCT00103857) | Merck Sharp & Dohme LLC | 2005-03-17 |
| Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED) (NCT00266812) | Merck Sharp & Dohme LLC | 2005-03-08 |
| Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) (NCT00335075) | Merck Sharp & Dohme LLC | 2005-03-02 |
| Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED) (NCT00704522) | Merck Sharp & Dohme LLC | 2005-03-01 |
| Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED) (NCT00202839) | Merck Sharp & Dohme LLC | 2005-03-01 |
| Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212) (NCT00255008) | Merck Sharp & Dohme LLC | 2005-03-01 |
| Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED) (NCT00105157) | Merck Sharp & Dohme LLC | 2005-03-01 |
| A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013) (NCT00127153) | Merck Sharp & Dohme LLC | 2005-03-01 |
| Antihypertensive Response to Losartan and Genetic Polymorphisms (NCT00617877) | Merck Sharp & Dohme LLC | 2005-03-01 |
| Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035) (NCT00106704) | Merck Sharp & Dohme LLC | 2005-03-01 |
| Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) (NCT00091559) | Merck Sharp & Dohme LLC | 2005-02-03 |
| Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED) (NCT00743431) | Merck Sharp & Dohme LLC | 2005-02-01 |
| A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) (NCT00100152) | Merck Sharp & Dohme LLC | 2005-02-01 |
| Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1) (NCT00104052) | Merck Sharp & Dohme LLC | 2005-02-01 |
| Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED) (NCT00255034) | Merck Sharp & Dohme LLC | 2005-02-01 |
| Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011) (NCT00432523) | Merck Sharp & Dohme LLC | 2005-01-20 |
| A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007) (NCT00109135) | Merck Sharp & Dohme LLC | 2005-01-01 |
| A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED) (NCT00100048) | Merck Sharp & Dohme LLC | 2005-01-01 |
| Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease (NCT00103714) | Merck Sharp & Dohme LLC | 2005-01-01 |
| A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012) (NCT00990821) | Merck Sharp & Dohme LLC | 2005-01-01 |
| A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED) (NCT00132769) | Merck Sharp & Dohme LLC | 2005-01-01 |
| Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy (NCT00120861) | Merck Sharp & Dohme LLC | 2005-01-01 |
| MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001) (NCT00099346) | Merck Sharp & Dohme LLC | 2005-01-01 |
| A Study to Compare Different Intubating Doses of Zemuron in Pediatric and Adolescent Subjects Under General Anesthesia (NCT00124722) | Merck Sharp & Dohme LLC | 2004-12-01 |
| A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED) (NCT00126451) | Merck Sharp & Dohme LLC | 2004-12-01 |
| Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243) (NCT00709059) | Merck Sharp & Dohme LLC | 2004-12-01 |
| Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED) (NCT00724958) | Merck Sharp & Dohme LLC | 2004-12-01 |
| Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685) (NCT00265395) | Merck Sharp & Dohme LLC | 2004-12-01 |
| Safety Study of a Refrigerator-stable Formulation of VARIVAX® (NCT00432731) | Merck Sharp & Dohme LLC | 2004-12-01 |
| Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers (NCT00099450) | Merck Sharp & Dohme LLC | 2004-12-01 |
| Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264) (NCT00725296) | Merck Sharp & Dohme LLC | 2004-12-01 |
| A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) (NCT00727961) | Merck Sharp & Dohme LLC | 2004-11-09 |
| A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) (NCT00863525) | Merck Sharp & Dohme LLC | 2004-11-01 |
| Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023) (NCT00095576) | Merck Sharp & Dohme LLC | 2004-11-01 |
| A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED) (NCT00770159) | Merck Sharp & Dohme LLC | 2004-11-01 |
| Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247) (NCT00705107) | Merck Sharp & Dohme LLC | 2004-11-01 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008) (NCT00750178) | Merck Sharp & Dohme LLC | 2004-11-01 |
| Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) (NCT00091572) | Merck Sharp & Dohme LLC | 2004-10-20 |
| Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012) (NCT00560833) | Merck Sharp & Dohme LLC | 2004-10-15 |
| An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023) (NCT00094757) | Merck Sharp & Dohme LLC | 2004-10-06 |
| Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) (NCT00093080) | Merck Sharp & Dohme LLC | 2004-10-01 |
| A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED) (NCT00779012) | Merck Sharp & Dohme LLC | 2004-10-01 |
| Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067) (NCT00727259) | Merck Sharp & Dohme LLC | 2004-10-01 |
| A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797) (NCT00124735) | Merck Sharp & Dohme LLC | 2004-10-01 |
| Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED) (NCT00779935) | Merck Sharp & Dohme LLC | 2004-10-01 |
| A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED) (NCT00109278) | Merck Sharp & Dohme LLC | 2004-10-01 |
| An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED) (NCT00095056) | Merck Sharp & Dohme LLC | 2004-10-01 |
| Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206) (NCT00723879) | Merck Sharp & Dohme LLC | 2004-10-01 |
| MK0524 Asthma POC Study (0524-008)(COMPLETED) (NCT00783601) | Merck Sharp & Dohme LLC | 2004-10-01 |
| A Study to Investigate Biomarkers of Skin Androgenization Following Testosterone Administration (0000-015)(COMPLETED). (NCT00969163) | Merck Sharp & Dohme LLC | 2004-10-01 |
| Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013) (NCT00535288) | Merck Sharp & Dohme LLC | 2004-09-15 |
| An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) (NCT00090285) | Merck Sharp & Dohme LLC | 2004-09-03 |
| Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002) (NCT00769418) | Merck Sharp & Dohme LLC | 2004-09-01 |
| To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053) (NCT00397956) | Merck Sharp & Dohme LLC | 2004-09-01 |
| An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024) (NCT00094770) | Merck Sharp & Dohme LLC | 2004-09-01 |
| Improving Management of Patients at High Risk for Osteoporotic Fractures (0000-038) (NCT00139438) | Merck Sharp & Dohme LLC | 2004-09-01 |
| Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027) (NCT00944450) | Merck Sharp & Dohme LLC | 2004-08-01 |